Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.

NCT03667716 is registered in ClinicalTrials.gov with Compugen Ltd as lead sponsor.

NCT NCT03667716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03667716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.
Lead sponsor
Compugen Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 6, 2018
Completion date
January 30, 2024
Enrollment
121 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, breast cancer, colo-rectal cancer, endometrial cancer, lung cancer, lung neoplasm, neoplasm malignant, ovarian cancer, ovarian neoplasm, triple negative breast cancer